《滬深兩市》上證微跌1點 創板跌1.4% 藥股受壓
內地昨日(18日)新增確診病例3,297宗,新增18,187宗本土無症狀感染者。人民銀行今日(19日)淨回籠100億元人民幣(下同),逆回購中標利率持平。人民幣兌美元中間價上調43點。內地首季GDP按年增長4.8%,勝預期。上證深成早段個別發展,其後反覆偏軟,全日分別跌0.05%至1.38%。
上證今早高見3,207點,惟其後反覆上落,3,200點關得而復失,全日跌1點或0.05%,收報3,194點;深成指一度跌穿11,600點水平,全日跌58點或0.5%,收報11,633點;創業板指數輕微低開後曾倒升,高見2,510點,惟其後再轉跌,全日收報2,453點,跌34點或1.38%。
國家醫保局稱繼續降低治療藥品價格,新冠藥物板塊受壓,科興(688136.SH)及誠達藥業(301201.SZ)跌逾8%,廣生堂(300436.SZ)跌5.3%。連花清瘟膠囊生產商以嶺藥業(002603.SZ)一度觸及跌停,全日收升0.06%。
煤炭股向好,上海能源(600508.SH)漲停。潞安環能(601699.SH)升近7%。
中資金融股變動不大,工行(601398.SH)升0.2%。建行(601939.SH)升0.3%報6.12元。
寧德時代(300750.SZ)擬斥約39.37億美元投資動力電池項目,股價收跌2.4%。
比亞迪(002594.SZ)料首季純利6.5億至9.5億元,按年增長174%至300%,股價收升2.4%。
科創板新股經緯恆潤(688326.SH)今日上市,全日收報100.01元,較上市價低17.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.